Mitigating the inhibition of human bile salt export pump by drugs: Opportunities provided by physicochemical property modulation, in silico modeling, and structural modification

Drug Metabolism and Disposition

Volumn 40, Issue 12, 2012, Pages 2332-2341

  Warner, Daniel J ^a   Chen, Hongming ^b   Cantin, Louis David ^a   Kenna, J Gerry ^a   Stahl, Simone ^a   Walker, Clare L ^a   Noeske, Tobias ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAZOLINE; BEZAFIBRATE; BILE SALT; BISMUTH SALICYLATE; BOSENTAN; BUPHENINE; EBSELEN; HUMAN BILE SALT EXPORT PUMP; LABETALOL; LEFLUNOMIDE; LETROZOLE; MEMBRANE PROTEIN; MEPINDOLOL; MEPYRAMINE; MESALAZINE; METYRAPONE; MIANSERIN; PARACETAMOL; PENICILLIN G; PROPRANOLOL; RAMELTEON; SALICYLAMIDE; TROPICAMIDE; UNCLASSIFIED DRUG;

ACCURACY; ACTIVE TRANSPORT; ARTICLE; BILE FLOW; CHOLESTATIC DRUG INDUCED LIVER INJURY; COMPUTER MODEL; DRUG CLASSIFICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; LIPOPHILICITY; LIVER CELL; LIVER INJURY; MOLECULAR SIZE; PHYSICAL CHEMISTRY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INHIBITION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; SUPPORT VECTOR MACHINE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE ACIDS AND SALTS; CELL LINE; DRUG-INDUCED LIVER INJURY; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84869104155     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.047068     Document Type: Article

References (43)

1. Abboud G and Kaplowitz N (2007) Drug-induced liver injury. Drug Saf 30:277-294.
2. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, and Artursson P (2008) Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem 51:5932-5942.
3. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science 323:1718-1722.
4. Arnold JR, Lerman CL, and Damewood JR (2004) Functional group fingerprints: augmenting hit and lead identification, in Proceedings of the 228th American Chemical Society National Meeting; 2004 Aug 22-26; Philadelphia, PA. American Chemical Society, Washington, DC.
5. Banić-Tomišić Z, Kojic-Prodic B, Sirola I (1997) Hydrogen bonds in the crystal packings of mesalazine and mesalazine hydrochloride. J Mol Struct 416:209-220.
6. Bruneau P (2001) Search for predictive generic model of aqueous solubility using Bayesian neural nets. J Chem Inf Comput Sci 41:1605-1616.
7. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, and Thompson RJ (2002) The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 123:1649-1658.
8. Davit-Spraul A, Gonzales E, Baussan C, and Jacquemin E (2009) Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 4:1-12.
9. Dawson S, Stahl S, Paul N, Barber J, and Kenna JG (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40:130-138.
10. DiMasi JA, Hansen RW, and Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151-185.
11. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, and Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223-231.
12. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, and Meier PJ (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273:10046-10050.
13. Ghose AK and Crippen GM (1987) Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. J Chem Inf Comput Sci 27:21-35.
14. Greaves P, Williams A, and Eve M (2004) First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 3:226-236.
15. Greer ML, Barber J, Eakins J, and Kenna JG (2010) Cell based approaches for evaluation of drug-induced liver injury. Toxicology 268:125-131.
16. Griffen E, Leach AG, Robb GR, and Warner DJ (2011) Matched molecular pairs as a medicinal chemistry tool. J Med Chem 54: 7739-7750.
17. Hitchcock SA (2012) Structural modifications that alter the P-glycoprotein efflux properties of compounds. J Med Chem 55:4877-4895.
18. Horikawa M, Kato Y, Tyson CA, and Sugiyama Y (2003) Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet 18:16-22.
19. Karlgren M, Ahlin G, Bergström CA, Svensson R, Palm J, and Artursson P (2012) In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res 29:411-426.
20. Katritzky A, Wang Y, Sild S, Tamm T, and Kalrelson M (1998) QSPR studies on vapor pressure, aqueous solubility, and the prediction of water-air partition coefficient. J Chem Inf Comp Sci 38:720-725.
21. Kido Y, Matsson P, and Giacomini KM (2011) Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54:4548-4558.
22. Kis E, Ioja E, Nagy T, Szente L, Herédi-Szabó K, and Krajcsi P (2009) Effect of membrane cholesterol on BSEP/Bsep activity: species specificity studies for substrates and inhibitors. Drug Metab Dispos 37:1878-1886.
23. Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, Feng B, Kubik R, Hanson J, Urda E, et al. (2006) Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 90:451-459.
24. Kramer JA, Sagartz JE, and Morris DL (2007) The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 6:636-649.
25. Leeson PD and Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6:881-890.
26. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26.
27. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW Jr, Lightfoot-Dunn R, and Hamadeh HK (2010) Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 118:485-500.
28. Mumoli N, Cei M, and Cosimi A (2006) Drug-related hepatotoxicity. N Engl J Med 354:2191-2193.
29. Noé J, Stieger B, and Meier PJ (2002) Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 123:1659-1666.
30. Paine SW, Barton P, Bird J, Denton R, Menochet K, Smith A, Tomkinson NP, and Chohan KK (2010) A rapid computational filter for predicting the rate of human renal clearance. J Mol Graph Model 29:529-537.
31. Paulusma CC, de Waart DR, Kunne C, Mok KS, and Elferink RP (2009) Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. J Biol Chem 284:9947-9954.
32. Pirmohamed M, Breckenridge AM, Kitteringham NR, and Park BK (1998) Adverse drug reactions. BMJ 316:1295-1298.
33. Saito H, Osumi M, Hirano H, Shin W, Nakamura R, and Ishikawa T (2009) Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11/BSEP). AAPS J 11:581-589.
34. Schuster D, Laggner C, and Langer T (2005) Why drugs fail - a study on side effects in new chemical entities. Curr Pharm Des 11:3545-3559.
35. Stålring JC, Carlsson LA, Almeida P, and Boyer S (2011) AZOrange - high performance open source machine learning for QSAR modeling in a graphical programming environment. J Cheminform 3:28-38.
36. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, and Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422-430.
37. Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, Claesson A, Page K, Dolgos H, and Kenna JG (2011) Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact 192:65-71.
38. U.S. Food and Drug Administration (2004) Innovation or stagnation: challenge and opportunity on the critical path to new medical products. U.S. Food and Drug Administration, Silver Spring, MD.
39. Wallace JL (2004) Acetaminophen hepatotoxicity: NO to the rescue. Br J Pharmacol 143:1-2.
40. Wang EJ, Casciano CN, Clement RP, and Johnson WW (2003) Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res 20:537-544.
41. Warner DJ, Griffen EJ, and St-Gallay SA (2010) WizePairZ: a novel algorithm to identify, encode, and exploit matched molecular pairs with unspecified cores in medicinal chemistry. J Chem Inf Model 50:1350-1357.
42. Wenlock MC, Austin RP, Barton P, Davis AM, and Leeson PD (2003) A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem 46:1250-1256.
43. Zimmerman HJ (1978) Drug-induced liver disease. Drugs 16:25-45.